Clinical Trial Update: Study of 23ME-01473 in Patients With Advanced Solid Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating 23ME-01473 in advanced solid malignancies (Phase 1/2) conducted by 23andMe, Inc. has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• 23ME-01473

Snippet

Sponsor: 23andMe, Inc. | Conditions: Solid Tumor | Phase 1, Phase 2 | Status: TERMINATED